Preoperative administration of intramuscular dezocine reduces postoperative pain for laparoscopic cholecystectomy

Yaomin Zhu*, Guixia Jing, Wei Yuan

Department of Anesthesiology, the First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi 710061, China

Received 21 January 2011, Revised 24 February 2011, Accepted 14 June 2011

Abstract

Postoperative pain is the most common complaint after laparoscopic cholecystectomy. This study was carried out to evaluate whether preoperative administration of intramuscular dezocine can provide postoperative analgesia and reduce postoperative opioid consumption in patients undergoing laparoscopic cholecystectomy. Patients (ASA I or II) scheduled for laparoscopic cholecystectomy were randomly assigned into intramuscular dezocine group (group 1) or intramuscular normal saline group (group 2). Dezocine and equal volume normal saline were administered intramuscularly 10 min before the induction of anesthesia. After operation, the severity of postoperative pain, postoperative fentanyl requirement, incidence and severity of side-effects were assessed. Postoperative pain and postoperative patient-controlled fentanyl consumption were reduced significantly in group 1 compared with group 2. The incidence and severity of side effects were similar between the two groups. Preoperative single-dose administration of intramuscular dezocine 0.1 mg/kg was effective in reducing postoperative pain and postoperative patient-controlled fentanyl requirement in patients undergoing laparoscopic cholecystectomy.

Keywords: dezocine, postoperative pain, laparoscopic cholecystectomy

INTRODUCTION

Postoperative pain is the most common complaint and the primary reason for prolonged convalescence after laparoscopic cholecystectomy. Intense acute pain after laparoscopic cholecystectomy could predict the development of chronic pain. Dezocine, a synthetic bridged aminotetralin with minimum side effects and low dependence liability, is a parenterally administered opioid analgesic that has both agonistic and antagonistic actions at opioid receptors. Dezocine was found to be 7 to 18 times as potent as morphine, and demonstrated slightly less antagonistic activity than nalorphine. One study showed that dezocine did not suppress abstinence in withdrawn morphine-dependent monkeys, nor did it produce dependence when administered chronically in monkeys. Some studies showed that dezocine was found to possess less potential for producing bronchoconstriction, respiratory depression, hypotension, and histamine-release than either morphine or pentazocine. In humans, dezocine was 8.6 times as potent as pentazocine in terms of respiratory depressant effects. In two clinical studies on the drug’s analgesic properties, the potency of 10 mg of dezocine was considered to be at least that of 50 mg of meperidine and of 10 mg of morphine. However, there are no reports on whether preoperative dezocine can reduce postoperative pain and the postoperative opioid requirement...
after laparoscopic cholecystectomy surgery.

This study was carried out to evaluate whether preoperative administration of intramuscular dezocine can provide postoperative analgesia and reduce postoperative opioid consumption in patients undergoing laparoscopic cholecystectomy under general anesthesia.

MATERIAL AND METHODS

Subjects

The study protocol was approved by the Institutional Human Ethics Committee of the First Affiliated Hospital of Medical College, Xi’an Jiaotong University, Xi’an, Shaanxi, China. Written informed consent was obtained from each patient. Based on a random, double blind design and control methods, 60 patients (ASA physical status I or II) scheduled for laparoscopic cholecystectomy were enrolled in this study. The patients were between 33 and 65 years old. The subjects were randomly assigned into two groups of 30 each with the help of a computer-generated table of random numbers, to receive either intramuscular dezocine 0.1 mg/kg (group 1) or normal saline in equal volume (group 2). Patients with history of chronic pain or daily intake of analgesics, uncontrolled medical disease (diabetes mellitus and hypertension), and inability to operate patient-controlled analgesia (PCA) device were excluded from the study. All the medications were provided by hospital pharmacy, and were identical.

Anesthesia

Dezocine and equal volume of normal saline were administered intramuscularly, 10 min before the induction of anesthesia by a staff nurse who was not involved in the study. Anesthesia technique was standardized in all the groups. Patients received totally intravenous anesthesia and mechanical ventilation. Anesthesia was induced with 4 μg/mL propofol by target-controlled-infusion (TCI), 3 μg/kg fentanyl, and 0.05 mg/kg midazolam. Neuromuscular blockade was achieved with 0.1 mg/kg vecuronium and the trachea was intubated. Anesthesia was maintained with propofol by TCI, remifentanil was continuously infused at the rate of 0.5-1.5 μg/(kg·min). Percutaneous oxygen saturation was maintained at 98% or more, and end-tidal carbon dioxide tension was maintained at 35 mmHg during surgery. The depth of anesthesia was maintained with the bispectral index at a score of 40-50 to ensure similar anesthetic depth in all patients. Acetated Ringer’s solution was infused at a rate of 6 to 8 mL/(kg·h) during surgery. In group 2, one patient who underwent conversion to open cholecystectomy was considered as drop-out and was therefore not included for further study. After satisfactory recovery, the patients were extubated and received intravenous injection fentanyl via PCA pump with an activated dose of 20 μg with a lockout interval of 15 min.

Clinical evaluation

The severity of postoperative pain, postoperative fentanyl requirement, incidence and severity of side-effects such as postoperative nausea and vomiting (PONV), headache, sedation, and respiratory depression were all assessed by an independent anesthesia registrar blinded to group allocation.

Assessment of pain both at rest and during coughing was done by a 100 mm visual analogue scale (VAS): 0, no pain; 100, worst imaginable pain[16]. VAS was measured at 0, 4, 8, 12, and 24 h after surgery by a trained nurse blinded to the study drug. The severity of PONV[17] was graded on a four-point ordinal scale (0, no nausea or vomiting; 1, mild nausea; 2, moderate nausea; 3, severe nausea with vomiting). Rescue antiemetic ondansetron 4 mg intravenous injection was given to all patients with PONV of grade ≥ 2. The Ramsay sedation scale (1, anxious, agitated, or restless; 2, cooperative, oriented, and tranquil; 3, response to command; 4, brisk response; 5, a sluggish response; 6, no response) was used to assess sedation; patients with a sedation scale of ≥ 4 were considered as sedated[18]. Respiratory depression was defined as ventilatory frequency ≤ 8 bpm and oxygen saturation < 90% without oxygen supplementation[19].

Statistical analysis

The subject who underwent conversion to open cholecystectomy in group 2 was not subjected to further statistical analysis. The SPSS 15.0 program was used to analyze the statistical data. Values are expressed as mean ± SD, or the number of patients. Patient characteristic data were analyzed with one-way ANOVA for continuous variables and Chi-square test for categorical variables. The VAS pain scores and postoperative PCA fentanyl consumption were analyzed with Student’s t-test. The incidences of side-effects and sedation were analyzed with Fisher’s exact test. Significance was determined at P < 0.05.

RESULTS

Baseline conditions

One subject who underwent conversion to open cholecystectomy was considered as drop-out after initial randomization and was therefore not included for further statistical analysis. There were no significant differences between the two groups with respect to
age, body weight, sex, duration of anesthesia and duration of surgery (Table 1).

**Table 1 Patient general characteristics**

|                      | Group 1 (n=30) | Group 2 (n=29) |
|----------------------|----------------|----------------|
| Age (y)              | 44±9           | 43±10          |
| Weight (kg)          | 64±12          | 65±10          |
| Sex (M/F)            | 18/12          | 16/13          |
| Duration of anaesthesia (min) | 62±31      | 65±33          |
| Duration of surgery (min) | 38±25      | 40±24          |

Group 1: patients who received intramuscular dezocine. Group 2: patients who received intramuscular saline at an equal volume as dezocine. There were no significant differences between group 1 and 2.

**VAS scores and fentanyl consumption after surgery**

The VAS scores at 0, 4, 8, 12, and 24 h after surgery at rest in group 1 were significantly lower than those in group 2; the VAS scores at 0, 4, 8, 12, and 24 h after surgery during coughing in group 1 were significantly lower than those in group 2 (Fig. 1). Postoperative patient-controlled fentanyl consumption were reduced significantly in group 1 (458.5±89.7 μg) compared with group 2 (856.3±101.2 μg, P < 0.01).

**Fig. 1 Postoperative VAS scores at 0, 4, 8, 12, and 24 h after surgery in two groups.** R2 compared with R1, C2 compared with C1, \(^{\text{c}}P < 0.05\) and \(^{\text{d}}P < 0.01\). VAS: visual analogue scale (0, no pain; 100, worst imaginable pain). R1: VAS scores at rest in group 1. C1: VAS scores during coughing in group 1. R2: VAS scores at rest in group 2. C2: VAS scores during coughing in group 2. Group 1: patients who received intramuscular dezocine. Group 2: patients who received intramuscular saline at an equal volume as dezocine.

**Sedation scores**

There were no significant differences in the number of patients in the different scales of Ramsay sedation scores (1, 2, 3 and 4) between two groups (Fig. 2).

**Fig. 2 The distribution of patients in the different scales of Ramsay sedation scores of the two groups.** There were no significant differences between group 1 and 2. Ramsay sedation score (1: anxious, agitated, or restless; 2: cooperative, oriented, and tranquil; 3: response to command; 4: brisk response). Group 1: patients who received intramuscular dezocine. Group 2: patients who received intramuscular saline at an equal volume as dezocine.

**The incidence of side-effects**

There were no significant differences in the number of patients in the incidence and severity of PONV (0, 1, 2 and 3) between the two groups (Fig. 3). The number of patients requiring antiemetics, incidence of headache, and respiratory depression were similar between two groups.

**Fig. 3 The distribution of patients in the different grades of PONV of the two groups.**

There were no significant differences between group 1 and 2. PONV: postoperative nausea and vomiting; 0: no nausea or vomiting; 1: mild nausea; 2: moderate nausea; 3: severe nausea with vomiting. Group 1: patients who received intramuscular dezocine. Group 2: patients who received intramuscular saline at an equal volume as dezocine.

**DISCUSSION**

Dezocine is an analgesic agent with opioid agonist and antagonist activity\(^{[20]}\). After parenteral administration of therapeutic doses, it is approximately equipotent with morphine, and has proved at least as an effective analgesic as morphine, pethidine and butorphanol in moderate to severe postoperative pain\(^{[21]}\). However, preliminary pharmacodynamic data indicate
that the ceiling of analgesic activity of dezocine occurs at a higher level of analgesia than that of reference agonist/antagonist agents. Additionally, the drug exhibited a morphine-like degree of anaesthetic-sparing activity in animals. Although long term data are very limited, single doses of dezocine are well tolerated, with mild and transient sedation and gastrointestinal upset the principal adverse effects\textsuperscript{[22,23]. In single analgesic doses, dezocine is a slightly more potent respiratory depressant than morphine\textsuperscript{[23]. Clinically, important haemodynamic changes have not been observed with usual analgesic doses of dezocine. As an agonist/antagonist opioid, the dependence liability of dezocine would be expected to be lower than that of pure agonist opioids\textsuperscript{[24].}

In our study, we observed that the VAS scores of postoperative pain at 0, 4, 8, 12, and 24 h after surgery and the doses of postoperative patient-controlled fentanyl consumption after surgery were reduced significantly in group 1 when compared with group 2. These results indicate that preoperative single-dose administration of intramuscular dezocine was effective in reducing both the static and the dynamic components of postoperative pain along with postoperative patient-controlled fentanyl consumption in subjects undergoing laparoscopic cholecystectomy. Camu et al.\textsuperscript{[25]} showed that dezocine 10 mg was less effective than meperidine but dezocine 15 mg showed a rapid onset of analgesic effect with long-lasting analgesia superior to meperidine. In Cohen et al.’s study\textsuperscript{[26]}, adult patients who had arthroscopic surgery under general anesthesia and requested postoperative pain relief were randomized to receive treatment in a double-blind protocol with 5 mg of intravenous dezocine, morphine, nalbuphine, or saline. The results showed that dezocine and morphine are more efficacious than nalbuphine in the management of early postoperative pain. As an alternate analgesic in this study, dezocine required fewer doses to achieve patient satisfaction and was thus more efficacious than morphine. In Ding et al.’s study\textsuperscript{[27]}, patients undergoing outpatient laparoscopic procedures received ketorolac (60 mg) or dezocine (6 mg) or fentanyl (100 μg) before the start of the operation. In the postanesthesia care unit, 61% of patients in the fentanyl group received analgesic drugs for persistent pain, compared with 34% and 25% in the ketorolac and dezocine groups, respectively, and less postoperative fentanyl was required in the ketorolac (22±33 μg) and dezocine (18±35 μg) groups, compared with the fentanyl (58±33 μg) group. The study by Finucane et al.\textsuperscript{[28]} indicates that a single 10 or 15 mg intramuscular injection of dezocine is safe and more effective than placebo for 4–6 h, respectively, in the treatment of moderate to severe postoperative pain, and both doses of dezocine provided long-lasting relief. The scores on all three efficacy scales were the highest with the 15 mg dose of dezocine after the first hour.

Our study showed that, in group 1, dezocine was administered intramuscularly 10 min before the induction of anesthesia; in group 2, equal volume saline was administered intramuscularly 10 min before the induction of anesthesia. The results showed that the severity of postoperative pain was reduced significantly at 0, 4, 8, 12, and 24 h after operation and postoperative fentanyl requirement was also reduced significantly in group 1 compared with group 2. The reason may be that dezocine administered intramuscularly before operation can produce pre-emptive analgesia and reduce the fentanyl doses during postoperative PCA in patients undergoing laparoscopic cholecystectomy. Dah et al.\textsuperscript{[29]} showed that pre-emptive analgesia has the potential to be more effective than a similar analgesic treatment initiated after surgery, and the immediate postoperative pain may be reduced and the development of chronic pain may be prevented.

Our data showed that there were no significant differences in the incidence and severity of sedation between the dezocine group and control group. The reason may be that the dose of dezocine which we used or the dose of fentanyl by patient-controlled consumption is small. Ramirez-Ruiz et al.\textsuperscript{[30]} showed that compared with ketorolac 60 mg, fentanyl 100 μg and dezocine 6 mg produced a greater decrease in the propofol sedation requirement during monitored anesthesia care. In Zacny et al.’s study\textsuperscript{[31]}, 10 healthy volunteers (six men and four women) were injected with 0, 2.5, 5.0, and 10 mg of dezocine in a double-blind fashion, and their results indicate that dezocine had a sedative effect in a dose-dependent fashion.

In our study, the incidence and severity of PONV, number of patients requiring antiemetics, incidence of headache, and respiratory depression were similar between the two groups. Camu et al.\textsuperscript{[25]} found that vital signs remained stable within satisfactory limits with no respiratory depression occurring after administration of 10 or 15 mg dezocine, side effects observed appeared to be dose-related. Some researchers found that dezocine was associated with an increased incidence of postoperative nausea and a delayed discharge time compared with ketorolac, and with an decreased incidence of postoperative nausea compared with morphine\textsuperscript{[27,32]. The difference in their results from our study could possibly be because we administered a smaller dose of dezocine against their starting
dose or because of the reduced postoperative patient-controlled fentanyl consumption or the difference in the nature of surgery. Limitations of the present study are that we did not evaluate the dose–response or the effect of continuation of therapy. Further studies are suggested in these areas.

In conclusion, preoperative single-dose administration of intramuscular dezocine 0.1 mg/kg was effective in reducing postoperative pain and postoperative patient-controlled fentanyl requirement in patients undergoing laparoscopic cholecystectomy. The side-effect profile was similar in both groups. We therefore suggest that preoperative single-dose administration of intramuscular dezocine is an effective method for reducing postoperative pain and fentanyl consumption in patients undergoing laparoscopic cholecystectomy.

References

[1] Kandil TS, El Hefnawy E. Shoulder pain following laparoscopic cholecystectomy: factors affecting the incidence and severity. J Laparoendosc Adv Surg Tech A 2010;20:677-82.
[2] Celik AS, Frat N, Celebi F, Guzey D, Kaplan R, Birol S, et al. Laparoscopic cholecystectomy and postoperative pain: is it affected by intra-abdominal pressure? Surg Laparosc Endosc Percutan Tech 2010;20:220-2.
[3] Bisgaard T, Kehlet H, Rosenberg J. Pain and convalescence after laparoscopic cholecystectomy. Eur J Surg 2001;167:84-96.
[4] Thesbjerg SE, Harboe KM, Bardram L, Rosenberg J. Sex differences in laparoscopic cholecystectomy. Surg Endosc 2010;24:3068-72.
[5] Bisgaard T, Rosenberg J, Kehlet H. From acute to chronic pain after laparoscopic cholecystectomy: a prospective follow-up analysis. Scand J Gastroenterol 2005;40:1538-64.
[6] Garg P, Thakur JD, Singh I. Lower abdominal wall pain and contusion in single-incision laparoscopic cholecystectomy. J Laparoendosc Adv Surg Tech A 2010;20:713-5.
[7] Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J. Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol 2006;6:3.
[8] Fischer BD, Miller LL, Henry FE, Picker MJ, Dykstra LA. Increased efficacy of micro-opioid agonist-induced antinociception by metabolotropic glutamate receptor antagonists in C57BL/6 mice: comparison with (+)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959). Psychopharmacology (Berl) 2008;198:271-8.
[9] Barrett AC, Smith ES, Picker MJ. Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. Eur J Pharmacol 2002;452:163-73.
[10] Terner JM, Barrett AC, Grossell E, Picker MJ. Influence of gonadectomy on the antinociceptive effects of opioids in male and female rats. Psychopharmacology (Berl) 2002;163:183-93.
[11] Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010;23:616-22.
[12] Hoelzler MG, Harvey RC, Lidbetter DA, Millis DL. Comparison of perioperative analgesic protocols for dogs undergoing tibial plateau leveling osteotomy. Vet Surg 2005;34:337-44.
[13] Strain EC, Preston KL, Liebson IA, Bigelow GE. Opioid antagonist effects of dezocine in opioid-dependent humans. Clin Pharmacol Ther 1996;60:206-17.
[14] O’Brien JJ, Benfield P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989;38:226-48.
[15] Lambrecht RW, Gildeimeister OS, Williams A, Pepe JA, Tortorelli KD, Bonkovsky HL. Effects of selected antihypertensives and analgesics on hepatic porphyrin accumulation: implications for clinical porphyria. Biochem Pharmacol 1999;58:387-96.
[16] Liu SS, Togioka BM, Hurley RW, Vu CM, Hanna MN, Murphy JD, et al. Methodological quality of randomized controlled trials of postoperative epidural analgesia: validation of the Epidural Analgesia Trial Checklist as a specific instrument to evaluate methodology. Reg Anesth Pain Med 2010;35:549-55.
[17] Jiang YH, Jiang W, Jiang LM, Lin GX, Yang H, Tan Y, et al. Clinical efficacy of acupuncture on the morphine-related side effects in patients undergoing spinal-epidural anesthesia and analgesia. Chin J Integr Med 2010;16:71-4.
[18] Lu CH, Chen JL, Wu CT, Liaw WJ, Yeh CC, Cherng CH, et al. Effect of epidural neuraxial blockade-dependent sedation on the Ramsay Sedation Scale and the composite auditory evoked potentials index in surgical intensive care patients. J Formos Med Assoc 2010;109:589-95.
[19] Cashman JN, Dolin J. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth 2004;93:212-23.
[20] Barrett AC, Smith ES, Picker MJ. Capsaicin-induced hyperalgesia and mu-opioid-induced antihyperalgesia in male and female Fischer 344 rats. J Pharmacol Exp Ther 2003;307:237-45.
[21] Walker EA, Picker MJ, Granger A, Dykstra LA. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther 2004;310:150-8.
[22] Gharagozlou P, Demirci H, David Clark J, Lameh J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 2003;3:1.
[23] Montanè V, Vallano A, Aguilerà C, Vidal X, Laporte JR. Analgesics for pain after traumatic or orthopaedic surgery: what is the evidence—a systematic review. Eur J Clin Pharmacol 2006;62:971-88.
[24] Smith H, Bruckenthal P. Implications of opioid anal-
Intramuscular dezocine reduces postoperative pain

[25] Camu F, Gepts E. Analgesic properties of dezocine for relief of postoperative pain. *Acta Anaesthesiol Belg* 1979;30 (Suppl):S183-91.

[26] Cohen RI, Edwards WT, Kezer EA, Ferrari DA, Liland AE, Smith ER. Serial intravenous doses of dezocine, morphine, and nalbuphine in the management of postoperative pain for outpatients. *Anesth Analg* 1993;77:533-9.

[27] Ding Y, White PF. Comparative effects of ketorolac, dezocine, and fentanyl as adjuvants during outpatient anesthesia. *Anesth Analg* 1992;75:566-71.

[28] Finucane BT, Floyd JB, Petro DJ. Postoperative pain relief: a double-blind comparison of dezocine, butorphanol, and placebo. *South Med J* 1986;79:548-52.

[29] Dahl JB, Moiniche S. Pre-emptive analgesia. *Br Med Bull* 2004;71:13-27.

[30] Ramirez-Ruiz M, Smith I, White PF. Use of analgesics during propofol sedation: a comparison of ketorolac, dezocine, and fentanyl. *J Clin Anesth* 1995;7:481-5.

[31] Zacny JP, Lichtor JL, de Wit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. *Anesth Analg* 1992;74:523-30.

[32] Barrett AC, Cook CD, Terner JM, Craft RM, Picker MJ. Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids. *Psychopharmacology* 2001;158:154-64.